ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
39 announcements
Fredun Pharmaceuticals Ltd reported revenue from operations of ₹265.9 Cr (+85.2% YoY) and net profit of ₹18.6 Cr (+97.9% YoY) for Q2 FY27.
Fredun Pharmaceuticals will hold a board meeting on 05 November 2026 to consider half-year results. Trading window stays closed until 48 hours after results.
Fredun Pharmaceuticals allotted 44,000 equity shares to three non-promoter investors on conversion of 14,667 warrants. The conversion follows the 1:2 bonus issue, which adjusted warrant entitlements.
Fredun Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026. The disclosure provides the equity holding structure for shareholders.
Fredun Pharmaceuticals filed a compliance certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018. It confirms the processing of dematerialized shares for the quarter.
Fredun Pharma announces strategic pet-care acquisitions, capacity expansion, and a 100% branded portfolio target by 2029. H1 FY27 business update outlines multi-pillar growth transformation.
Fredun Pharmaceuticals allotted 1,82,400 equity shares upon the conversion of 60,800 warrants. The company received total consideration of ₹7.60 Crore for this warrant conversion.
Fredun Pharmaceuticals has allotted 1,82,400 equity shares following the conversion of 60,800 warrants into equity shares, completing the preferential issue conversion process.
Fredun Pharmaceuticals allotted 3,61,599 equity shares following the conversion of 1,20,533 warrants. This allotment was executed at an issue price of Rs. 1,250 per warrant.
Fredun Pharmaceuticals acquired a 26% stake in ₹300 Crore-valued Goodman Vetcare, a dedicated pet pharmacy chain. Plans target PAN-India expansion with ~₹100 Cr revenue by FY31.
Fredun Pharmaceuticals allotted 2,71,200 equity shares following the conversion of 90,400 warrants. The board approved the issuance, raising Rs 11.3 Crore in total consideration.
Fredun Pharmaceuticals announced expansion of its Furlicks pet wellness range from 6 to 22 SKUs. The press release signals accelerated growth in the pet wellness segment.
Fredun Pharmaceuticals acquires pet-wellness brand Furlicks from USV and Wellbeing Nutrition. The deal marks strategic entry into India's pet-wellness market with plans to launch 44 new SKUs.
Fredun Pharmaceuticals launched PAWTALKS, a digital knowledge platform for pet and animal healthcare. Initially debuting on YouTube and Instagram, it connects veterinary experts with pet owners.
Fredun Pharmaceuticals delivered explosive Q1 FY27 growth with standalone income rising 90.44% YoY to INR 228.25 cr and PAT up 94.63% to INR 13.17 cr.
Fredun Pharmaceuticals submitted its Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its prior preferential allotment.
Fredun Pharmaceuticals reported Q1 FY27 total income of ₹228.25 Crore, a 90% YoY increase. Net profit rose 94.6% to ₹13.17 Crore during the same period.
Fredun Pharmaceuticals Ltd reported revenue from operations of ₹227.8 Cr (+90.8% YoY) and net profit of ₹13.1 Cr (+92.6% YoY) for Q1 FY27.
Fredun Pharmaceuticals Ltd has scheduled a board meeting on August 5, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Fredun Pharmaceuticals allotted 1.10 crore bonus shares in a 2:1 ratio. Post-issue paid-up capital increased to Rs 16.54 crore from Rs 5.51 crore.
Fredun Pharmaceuticals set July 16, 2026, as the record date for its 2:1 bonus issue. Shareholders will receive two new shares for every one held.
Fredun Pharmaceuticals held its 39th Annual General Meeting on June 30, 2026. The meeting covered ordinary and special resolutions, including dividend declarations.
Fredun delivered strong Q4 FY26 performance with 27% revenue growth and 56% PAT growth. Transitioning from contract manufacturing to high-margin consumer brands in pet care, mobility, and anti-aging segments.
Fredun Pharmaceuticals reported strong Q3 FY'26 results with 57% revenue growth and 96% PAT growth, driven by its 'new-age' brands in pet care, nutrition, and dermaceutics.
Fredun Pharmaceuticals set June 23, 2026, as the record date for a 7% final dividend. The payment remains subject to shareholder approval at the upcoming AGM.
Fredun Pharmaceuticals scheduled its 39th AGM for June 30, 2026. The share transfer books will remain closed from June 24 to June 30 for meeting purposes.
Fredun Pharmaceuticals released its FY2025-26 Annual Report and 39th AGM notice. Shareholders will vote on a 2:1 bonus issue and a 7% final dividend.
Fredun Pharmaceuticals filed its FY26 Annual Secretarial Compliance Report. The auditor noted temporary board composition non-compliance due to an executive director's sudden demise.
Fredun Pharmaceuticals reported audited FY26 financial results and recommended a 7% final dividend. The board also approved a 2:1 bonus share issue and increased authorized capital.
Fredun Pharmaceuticals announced a 2:1 bonus issue following strong FY26 performance. The move reflects management's confidence in long-term growth and commitment to shareholder wealth.